Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HCW Biologics (HCWB) Net Margin (2022 - 2025)

HCW Biologics (HCWB) has disclosed Net Margin for 4 consecutive years, with 29181.36% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin fell 2826492.0% year-over-year to 29181.36%, compared with a TTM value of 3281.82% through Sep 2025, down 221063.0%, and an annual FY2024 reading of 1173.09%, down 25817.0% over the prior year.
  • Net Margin was 29181.36% for Q3 2025 at HCW Biologics, up from 56053.05% in the prior quarter.
  • Across five years, Net Margin topped out at 65.99% in Q1 2022 and bottomed at 56053.05% in Q2 2025.
  • Average Net Margin over 4 years is 10045.54%, with a median of 813.2% recorded in 2023.
  • The sharpest move saw Net Margin soared 1235692bps in 2024, then crashed -5358394bps in 2025.
  • Year by year, Net Margin stood at 429.49% in 2022, then tumbled by -89bps to 813.2% in 2023, then decreased by -6bps to 861.87% in 2024, then plummeted by -3286bps to 29181.36% in 2025.
  • Business Quant data shows Net Margin for HCWB at 29181.36% in Q3 2025, 56053.05% in Q2 2025, and 43862.27% in Q1 2025.